Safety and Efficacy of Targeted-Dose Busulfan and Bortezomib as a Conditioning Regimen for Patients with Relapsed Multiple Myeloma Undergoing a Second Autologous Blood Progenitor Cell Transplantation

• Published in: Biology of blood and marrow transplantation 2014-12, Vol.20 (12), p.1949-1957
• Main Authors: Freytes, César O, Toro, Juan J, Yeh, Rosa F, Stadtmauer, Edward A, Ratanatharathorn, Voravit, Akpek, Görgün, Sahovic, Entezam, Tricot, Guido J, Shaughnessy, Paul J, White, Darrell J, Rodriguez, Tulio E, Solomon, Scott R, Yu, Louie H, Zhao, Cathy, Patil, Shiva, Armstrong, Elizabeth, Smith, Angela, Elekes, Agnes, Kato, Kazunobu, Reece, Donna E
• Format: Article
• Language: English
• Subjects: Adolescent; Adult; Aged; Antineoplastic Agents - administration & dosage; Antineoplastic Agents - adverse effects; Antineoplastic Agents - pharmacokinetics; Autografts; Autologous transplantation; Boronic Acids - administration & dosage; Boronic Acids - adverse effects; Boronic Acids - pharmacokinetics; Bortezomib; Busulfan; Busulfan - administration & dosage; Busulfan - adverse effects; Busulfan - pharmacokinetics; Disease-Free Survival; Female; Follow-Up Studies; Hematology, Oncology and Palliative Medicine; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Multiple myeloma; Multiple Myeloma - blood; Multiple Myeloma - mortality; Multiple Myeloma - therapy; Myeloablative Agonists - administration & dosage; Myeloablative Agonists - adverse effects; Myeloablative Agonists - pharmacokinetics; Prospective Studies; Pyrazines - administration & dosage; Pyrazines - adverse effects; Pyrazines - pharmacokinetics; Survival Rate; Transplantation Conditioning
• ISSN: 1083-8791; 1523-6536
• DOI: 10.1016/j.bbmt.2014.08.007

Abstract Patients with multiple myeloma (MM) who relapse after autologous transplantation have limited therapeutic options. We conducted a prospective, multicenter, phase IIa study to investigate the safety and efficacy of i.v. busulfan (Bu) in combination with bortezomib as a conditioning regimen for a second autotransplantation. Because a safe Bu exposure was unknown in patients receiving this combination, Bu was initially targeted to a total area under the concentration–time curve (AUC) of 20,000 μM × minute. As no concentration-limiting toxicity was observed in 6 patients, this Bu exposure was utilized in the following treatment cohort (n = 24). Individualized Bu dose, based on test dose .8 mg/kg pharmacokinetics (PK), was administered daily for 4 consecutive days starting 5 days before transplantation, followed by a single dose of bortezomib (1.3 mg/m2 ) 1 day before transplantation. The total mean dose of i.v. Bu (including the test dose and 4-day administration) was 14.2 mg/kg (standard deviation = 2.48; range, 8.7 to 19.2). Confirmatory PK demonstrated that only 2 of 30 patients who underwent transplantation were dosed outside the Bu AUC target and dose adjustments were made for the last 2 doses of i.v. Bu. The median age was 59 years (range, 48 to 73). Median time from first to second transplantation was 28.0 months (range, 12 to 119). Of 26 evaluable patients, 10 patients attained a partial response (PR) or better at 3 months after transplantation, with 2 patients attaining a complete response. At 6 months after transplantation, 5 of 12 evaluable patients had maintained or improved their disease status. Median progression-free survival was 191 days, whereas median overall survival was not reached during the study period. The most common grade 3 and 4 toxicities were febrile neutropenia (50.0%) and stomatitis (43.3%). One transplantation-related death was observed. A combination of dose-targeted i.v. Bu and bortezomib induced PR or better in one third of patients with MM who underwent a second autotransplantation, with acceptable toxicity.